_id
6919e2a73c536f8df2317fc6
Ticker
0RNK.LSE
Name
Inventiva S.A.
Exchange
LSE
Address
50 rue de Dijon, Daix, France, 21121
Country
UK
Sector
Industry
Currency
EUR
Website
https://inventivapharma.com
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Last Close
3.85143
Volume
4570
Current Price
3.8775
Change
1.9101995882048923
Last Updated
2025-12-29T14:49:20.827Z
Image
https://logo.clearbit.com/inventivapharma.com
Ipo Date
-
Market Cap
72433432
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
4454000
Cost Of Revenue
1704000
Gross Profit
2750000
Operating Expenses
59552000
Operating Income
-56802000
Interest Expense
9745000
Pretax Income
-177510000
Net Income
-175882000
Eps
-1.6159737983688223
Dividends Per Share
-
Shares Outstanding
22257300
Income Tax Expense
-1628000
EBITDA
-165841000
Operating Margin
-1275.303098338572
Total Other Income Expense Net
-120708000
Cash
122076000
Short Term Investments
-
Receivables
22792000
Inventories
-
Total Current Assets
172374000
Property Plant Equipment
3985000
Total Assets
178518000
Payables
34703000
Short Term Debt
5533000
Long Term Debt
-
Total Liabilities
187866000
Equity
-9346000
Bs_currency_symbol
-
Depreciation
1704000
Change In Working Capital
-1645000
Cash From Operations
-53893000
Capital Expenditures
57000
Cash From Investing
-24799000
Cash From Financing
104949000
Net Change In Cash
25512000
Cf_currency_symbol
-
PE
-
PB
-45.15575525251444
ROE
1881.8959982880376
ROA
-98.52339820074167
FCF
-53950000
Fcf Percent
-12.112707678491244
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
2.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
6.8
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
4.5
Net Net Investing Score
2
Quality Investing Score
3
Value Investing Score
3
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
4454000
Quarters > 0 > income Statement > cost Of Revenue
1704000
Quarters > 0 > income Statement > gross Profit
2750000
Quarters > 0 > income Statement > operating Expenses
59552000
Quarters > 0 > income Statement > operating Income
-56802000
Quarters > 0 > income Statement > interest Expense
9745000
Quarters > 0 > income Statement > pretax Income
-177510000
Quarters > 0 > income Statement > net Income
-175882000
Quarters > 0 > income Statement > eps
-1.6159737983688223
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
108839636
Quarters > 0 > income Statement > income Tax Expense
-1628000
Quarters > 0 > income Statement > EBITDA
-165841000
Quarters > 0 > income Statement > operating Margin
-1275.303098338572
Quarters > 0 > income Statement > total Other Income Expense Net
-120708000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
122076000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
22792000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
172374000
Quarters > 0 > balance Sheet > property Plant Equipment
3985000
Quarters > 0 > balance Sheet > total Assets
178518000
Quarters > 0 > balance Sheet > payables
34703000
Quarters > 0 > balance Sheet > short Term Debt
5533000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
187866000
Quarters > 0 > balance Sheet > equity
-9346000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-175882000
Quarters > 0 > cash Flow > depreciation
1704000
Quarters > 0 > cash Flow > change In Working Capital
-1645000
Quarters > 0 > cash Flow > cash From Operations
-53893000
Quarters > 0 > cash Flow > capital Expenditures
57000
Quarters > 0 > cash Flow > cash From Investing
-24799000
Quarters > 0 > cash Flow > cash From Financing
104949000
Quarters > 0 > cash Flow > net Change In Cash
25512000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-1.6159737983688223
Quarters > 0 > ratios > PB
-45.15575525251444
Quarters > 0 > ratios > ROE
1881.8959982880376
Quarters > 0 > ratios > ROA
-98.52339820074167
Quarters > 0 > ratios > FCF
-53950000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-12.112707678491244
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
11990000
Quarters > 1 > income Statement > cost Of Revenue
526000
Quarters > 1 > income Statement > gross Profit
11464000
Quarters > 1 > income Statement > operating Expenses
56773000
Quarters > 1 > income Statement > operating Income
-45309000
Quarters > 1 > income Statement > interest Expense
6979000
Quarters > 1 > income Statement > pretax Income
-134989000
Quarters > 1 > income Statement > net Income
-135183000
Quarters > 1 > income Statement > eps
-2.000479198696672
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
67575309
Quarters > 1 > income Statement > income Tax Expense
194000
Quarters > 1 > income Statement > EBITDA
-46324000
Quarters > 1 > income Statement > operating Margin
-377.88990825688074
Quarters > 1 > income Statement > total Other Income Expense Net
-89680000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
96563000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
12157000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
111511000
Quarters > 1 > balance Sheet > property Plant Equipment
5005000
Quarters > 1 > balance Sheet > total Assets
118967000
Quarters > 1 > balance Sheet > payables
32862000
Quarters > 1 > balance Sheet > short Term Debt
5868000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
225613000
Quarters > 1 > balance Sheet > equity
-106646000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-135183000
Quarters > 1 > cash Flow > depreciation
5198000
Quarters > 1 > cash Flow > change In Working Capital
7012000
Quarters > 1 > cash Flow > cash From Operations
-37586000
Quarters > 1 > cash Flow > capital Expenditures
333000
Quarters > 1 > cash Flow > cash From Investing
-167000
Quarters > 1 > cash Flow > cash From Financing
123024000
Quarters > 1 > cash Flow > net Change In Cash
86417000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-2.000479198696672
Quarters > 1 > ratios > PB
-2.456944101489976
Quarters > 1 > ratios > ROE
126.7586219830092
Quarters > 1 > ratios > ROA
-113.6306706901914
Quarters > 1 > ratios > FCF
-37919000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-3.1625521267723102
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
2734000
Quarters > 2 > income Statement > cost Of Revenue
526000
Quarters > 2 > income Statement > gross Profit
2734000
Quarters > 2 > income Statement > operating Expenses
54983000
Quarters > 2 > income Statement > operating Income
-52249000
Quarters > 2 > income Statement > interest Expense
5263000
Quarters > 2 > income Statement > pretax Income
-48910000
Quarters > 2 > income Statement > net Income
-49029000
Quarters > 2 > income Statement > eps
-0.9431901866667816
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
51982093
Quarters > 2 > income Statement > income Tax Expense
119000
Quarters > 2 > income Statement > EBITDA
-51818000
Quarters > 2 > income Statement > operating Margin
-1911.0826627651793
Quarters > 2 > income Statement > total Other Income Expense Net
3339000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
10147000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
10740000
Quarters > 2 > balance Sheet > inventories
393000
Quarters > 2 > balance Sheet > total Current Assets
28608000
Quarters > 2 > balance Sheet > property Plant Equipment
7980000
Quarters > 2 > balance Sheet > total Assets
39426000
Quarters > 2 > balance Sheet > payables
36583000
Quarters > 2 > balance Sheet > short Term Debt
5726000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
118485000
Quarters > 2 > balance Sheet > equity
-79059000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-49029000
Quarters > 2 > cash Flow > depreciation
431000
Quarters > 2 > cash Flow > change In Working Capital
2597000
Quarters > 2 > cash Flow > cash From Operations
-48342000
Quarters > 2 > cash Flow > capital Expenditures
255000
Quarters > 2 > cash Flow > cash From Investing
8912000
Quarters > 2 > cash Flow > cash From Financing
22568000
Quarters > 2 > cash Flow > net Change In Cash
-16771000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.9431901866667816
Quarters > 2 > ratios > PB
-2.549495511042386
Quarters > 2 > ratios > ROE
62.01570978636208
Quarters > 2 > ratios > ROA
-124.35702328412724
Quarters > 2 > ratios > FCF
-48597000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-17.775054864667155
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
16541000
Quarters > 3 > income Statement > cost Of Revenue
558000
Quarters > 3 > income Statement > gross Profit
15983000
Quarters > 3 > income Statement > operating Expenses
63689000
Quarters > 3 > income Statement > operating Income
-47706000
Quarters > 3 > income Statement > interest Expense
3260000
Quarters > 3 > income Statement > pretax Income
-54543000
Quarters > 3 > income Statement > net Income
-55157000
Quarters > 3 > income Statement > eps
-1.1335461978698118
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
48658802
Quarters > 3 > income Statement > income Tax Expense
614000
Quarters > 3 > income Statement > EBITDA
-47985000
Quarters > 3 > income Statement > operating Margin
-288.4106160449791
Quarters > 3 > income Statement > total Other Income Expense Net
-6837000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
26918000
Quarters > 3 > balance Sheet > short Term Investments
70000
Quarters > 3 > balance Sheet > receivables
15707000
Quarters > 3 > balance Sheet > inventories
417000
Quarters > 3 > balance Sheet > total Current Assets
48189000
Quarters > 3 > balance Sheet > property Plant Equipment
9127000
Quarters > 3 > balance Sheet > total Assets
69561000
Quarters > 3 > balance Sheet > payables
37679000
Quarters > 3 > balance Sheet > short Term Debt
5308000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
101592000
Quarters > 3 > balance Sheet > equity
-32031000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-55157000
Quarters > 3 > cash Flow > depreciation
1361000
Quarters > 3 > cash Flow > change In Working Capital
12795000
Quarters > 3 > cash Flow > cash From Operations
-36381000
Quarters > 3 > cash Flow > capital Expenditures
310000
Quarters > 3 > cash Flow > cash From Investing
-29000
Quarters > 3 > cash Flow > cash From Financing
31234000
Quarters > 3 > cash Flow > net Change In Cash
-4322000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-1.1335461978698118
Quarters > 3 > ratios > PB
-5.89037197574225
Quarters > 3 > ratios > ROE
172.19880740532608
Quarters > 3 > ratios > ROA
-79.29299463779992
Quarters > 3 > ratios > FCF
-36691000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-2.2181851157729278
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
14724000
Annuals > 0 > income Statement > cost Of Revenue
5526000
Annuals > 0 > income Statement > gross Profit
9198000
Annuals > 0 > income Statement > operating Expenses
106756000
Annuals > 0 > income Statement > operating Income
-97558000
Annuals > 0 > income Statement > interest Expense
12178000
Annuals > 0 > income Statement > pretax Income
-183899000
Annuals > 0 > income Statement > net Income
-184212000
Annuals > 0 > income Statement > eps
-3.0815657904643996
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
59778701
Annuals > 0 > income Statement > income Tax Expense
313000
Annuals > 0 > income Statement > EBITDA
-96695000
Annuals > 0 > income Statement > operating Margin
-662.5781037761477
Annuals > 0 > income Statement > total Other Income Expense Net
-86341000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
96563000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
12157000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
111511000
Annuals > 0 > balance Sheet > property Plant Equipment
5005000
Annuals > 0 > balance Sheet > total Assets
118967000
Annuals > 0 > balance Sheet > payables
32862000
Annuals > 0 > balance Sheet > short Term Debt
5868000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
225613000
Annuals > 0 > balance Sheet > equity
-106646000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-184212000
Annuals > 0 > cash Flow > depreciation
5198000
Annuals > 0 > cash Flow > change In Working Capital
7012000
Annuals > 0 > cash Flow > cash From Operations
-85928000
Annuals > 0 > cash Flow > capital Expenditures
333000
Annuals > 0 > cash Flow > cash From Investing
8745000
Annuals > 0 > cash Flow > cash From Financing
145592000
Annuals > 0 > cash Flow > net Change In Cash
69646000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-3.0815657904643996
Annuals > 0 > ratios > PB
-2.1692662910001315
Annuals > 0 > ratios > ROE
172.732216867018
Annuals > 0 > ratios > ROA
-154.84293963872335
Annuals > 0 > ratios > FCF
-86261000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-5.85853029068188
Annuals > 0 > health Score
31
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
17477000
Annuals > 1 > income Statement > cost Of Revenue
-23000
Annuals > 1 > income Statement > gross Profit
17500000
Annuals > 1 > income Statement > operating Expenses
120186000
Annuals > 1 > income Statement > operating Income
-102709000
Annuals > 1 > income Statement > interest Expense
5224000
Annuals > 1 > income Statement > pretax Income
-109819000
Annuals > 1 > income Statement > net Income
-110426000
Annuals > 1 > income Statement > eps
-2.434875846931673
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
45351799
Annuals > 1 > income Statement > income Tax Expense
607000
Annuals > 1 > income Statement > EBITDA
-102041000
Annuals > 1 > income Statement > operating Margin
-587.6809521084854
Annuals > 1 > income Statement > total Other Income Expense Net
-7110000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
26918000
Annuals > 1 > balance Sheet > short Term Investments
70000
Annuals > 1 > balance Sheet > receivables
15707000
Annuals > 1 > balance Sheet > inventories
417000
Annuals > 1 > balance Sheet > total Current Assets
48189000
Annuals > 1 > balance Sheet > property Plant Equipment
9125000
Annuals > 1 > balance Sheet > total Assets
69561000
Annuals > 1 > balance Sheet > payables
37679000
Annuals > 1 > balance Sheet > short Term Debt
5308000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
101592000
Annuals > 1 > balance Sheet > equity
-32032000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-110426000
Annuals > 1 > cash Flow > depreciation
2599000
Annuals > 1 > cash Flow > change In Working Capital
17307000
Annuals > 1 > cash Flow > cash From Operations
-81614000
Annuals > 1 > cash Flow > capital Expenditures
540000
Annuals > 1 > cash Flow > cash From Investing
-7731000
Annuals > 1 > cash Flow > cash From Financing
29081000
Annuals > 1 > cash Flow > net Change In Cash
-59818000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-2.434875846931673
Annuals > 1 > ratios > PB
-5.4792539376248754
Annuals > 1 > ratios > ROE
344.7365134865135
Annuals > 1 > ratios > ROA
-158.74699903681662
Annuals > 1 > ratios > FCF
-82154000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-4.700692338502031
Annuals > 1 > health Score
31
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
12179000
Annuals > 2 > income Statement > cost Of Revenue
995000
Annuals > 2 > income Statement > gross Profit
11184000
Annuals > 2 > income Statement > operating Expenses
74167000
Annuals > 2 > income Statement > operating Income
-57110000
Annuals > 2 > income Statement > interest Expense
755000
Annuals > 2 > income Statement > pretax Income
-54294000
Annuals > 2 > income Statement > net Income
-54274000
Annuals > 2 > income Statement > eps
-1.3093932670059243
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
41449732
Annuals > 2 > income Statement > income Tax Expense
-20000
Annuals > 2 > income Statement > EBITDA
-57719000
Annuals > 2 > income Statement > operating Margin
-468.9219147713277
Annuals > 2 > income Statement > total Other Income Expense Net
2816000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
86737000
Annuals > 2 > balance Sheet > short Term Investments
1048000
Annuals > 2 > balance Sheet > receivables
9343000
Annuals > 2 > balance Sheet > inventories
373000
Annuals > 2 > balance Sheet > total Current Assets
106383000
Annuals > 2 > balance Sheet > property Plant Equipment
7386000
Annuals > 2 > balance Sheet > total Assets
116004000
Annuals > 2 > balance Sheet > payables
19359000
Annuals > 2 > balance Sheet > short Term Debt
5851000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
70528000
Annuals > 2 > balance Sheet > equity
45476000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-54274000
Annuals > 2 > cash Flow > depreciation
1698000
Annuals > 2 > cash Flow > change In Working Capital
5713000
Annuals > 2 > cash Flow > cash From Operations
-44928000
Annuals > 2 > cash Flow > capital Expenditures
561000
Annuals > 2 > cash Flow > cash From Investing
8868000
Annuals > 2 > cash Flow > cash From Financing
37268000
Annuals > 2 > cash Flow > net Change In Cash
183000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-1.3093932670059243
Annuals > 2 > ratios > PB
3.5273652660744133
Annuals > 2 > ratios > ROE
-119.34646846688364
Annuals > 2 > ratios > ROA
-46.7863177131823
Annuals > 2 > ratios > FCF
-45489000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-3.7350357172181625
Annuals > 2 > health Score
19
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
4194000
Annuals > 3 > income Statement > cost Of Revenue
1017000
Annuals > 3 > income Statement > gross Profit
3177000
Annuals > 3 > income Statement > operating Expenses
56309000
Annuals > 3 > income Statement > operating Income
-52114000
Annuals > 3 > income Statement > interest Expense
142000
Annuals > 3 > income Statement > pretax Income
-49272000
Annuals > 3 > income Statement > net Income
-49636000
Annuals > 3 > income Statement > eps
-1.2672540690712188
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
39168152
Annuals > 3 > income Statement > income Tax Expense
364000
Annuals > 3 > income Statement > EBITDA
-52271000
Annuals > 3 > income Statement > operating Margin
-1242.5846447305676
Annuals > 3 > income Statement > total Other Income Expense Net
2843000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
86553000
Annuals > 3 > balance Sheet > short Term Investments
8829000
Annuals > 3 > balance Sheet > receivables
11587000
Annuals > 3 > balance Sheet > inventories
392000
Annuals > 3 > balance Sheet > total Current Assets
115578000
Annuals > 3 > balance Sheet > property Plant Equipment
3198000
Annuals > 3 > balance Sheet > total Assets
121985000
Annuals > 3 > balance Sheet > payables
14602000
Annuals > 3 > balance Sheet > short Term Debt
1282000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
33118000
Annuals > 3 > balance Sheet > equity
88867000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-49635000
Annuals > 3 > cash Flow > depreciation
-1288000
Annuals > 3 > cash Flow > change In Working Capital
979000
Annuals > 3 > cash Flow > cash From Operations
-47629000
Annuals > 3 > cash Flow > capital Expenditures
534000
Annuals > 3 > cash Flow > cash From Investing
-1793000
Annuals > 3 > cash Flow > cash From Financing
25447000
Annuals > 3 > cash Flow > net Change In Cash
-19134000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-1.2672540690712188
Annuals > 3 > ratios > PB
1.7057034471738666
Annuals > 3 > ratios > ROE
-55.854254110074606
Annuals > 3 > ratios > ROA
-40.6902488010821
Annuals > 3 > ratios > FCF
-48163000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-11.483786361468765
Annuals > 3 > health Score
34
Valuation > metrics > PE
-1.6159737983688223
Valuation > metrics > PB
-45.15575525251444
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
1881.8959982880376
Profitability > metrics > ROA
-102.03510970331952
Profitability > metrics > Net Margin
-39.48854961832061
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-5.8288353001539255
Risk > final Score
7
Risk > verdict
High
Liquidity > metrics > Current Ratio
4.284073963614674
Liquidity > metrics > Quick Ratio
4.284073963614674
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
40
Prev Profitabilities > 1
40
Prev Profitabilities > 2
40
Prev Risks > 0
4
Prev Risks > 1
-10
Prev Risks > 2
-29
Prev Liquidities > 0
100
Prev Liquidities > 1
43
Prev Liquidities > 2
78
Updated At
2026-01-20T22:58:57.228Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2020-06-30
Earnings History > 1 > report Date
2020-06-30
Earnings History > 1 > date
2020-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.2872
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-03-31
Earnings History > 2 > report Date
2020-03-31
Earnings History > 2 > date
2020-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.2341
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of Inventiva S.A.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2020-06-30
EPS Actual
-0.2872
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.